Ethical perspectives on pharmacogenomic profiling in the drug development process (original) (raw)

• Evans, W. E. & Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491 (1999).
  Article CAS Google Scholar
• Rioux, P. P. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am. J. Health Syst. Pharm. 57, 887–898 (2000).
  Article CAS Google Scholar
• McLeod, H. L. & Evans, W. E. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 41, 101–121 (2001).
  Article CAS Google Scholar
• Norton, R. M. Clinical pharmacogenomics: applications in pharmaceutical R & D. Drug Discov. Today 6, 180–185 (2001).This paper provides a good overview of the types of pharmacogenomics trial that are underway at present, and why the industry might view pharmacogenomics as a potentially powerful tool in its armament.
  Article Google Scholar
• Classen, D. C., Pestotnik, S. L., Evans, R. S. & Lloyd, J. F. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277, 301–306 (1997).
  Article CAS Google Scholar
• Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200–1205 (1998).
  Article CAS Google Scholar
• Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA 286, 2270–2279 (2001).This is an important systematic review that gives the reader a good understanding of how genetic polymorphisms might be associated with adverse drug reactions.
  Article CAS Google Scholar
• Primohamed, M. & Park, B. K. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298–305 (2001).
  Article Google Scholar
• Persidis, A. Pharmacogenomics. Nature Biotechnol. 18, IT40–IT42 (2000).
  Google Scholar
• Arledge, T., Freeman, A., Arbuckle, J., Mosteller, M. & Manasco, P. Applications of pharmacogenetics to drug development: the Glaxo Wellcome experience. Drug Metab. Rev. 32, 387–394 (2000).
  Article CAS Google Scholar
• Furuta, T. et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 69, 158–168 (2001).
  Article CAS Google Scholar
• Lessard, E. et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9, 435–443 (1999).
  Article CAS Google Scholar
• Drazen, J. M. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168–170 (1999).
  Article CAS Google Scholar
• Israel, E. et al. Effect of polymorphism of the β(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int. Arch. Allergy Immunol. 124, 183–186 (2001).
  Article CAS Google Scholar
• Poirier, J. et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl Acad. Sci. USA 92, 12260–12264 (1995).
  Article CAS Google Scholar
• Richard, F. et al. APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet 349, 539–540 (1997).
  Article CAS Google Scholar
• Rigaud, S. et al. The apolipoprotein E4 allele and the response to tacrine therapy in Alzheimer's disease. Eur. J. Neurol. 7, 255–258 (2000).
  Article CAS Google Scholar
• Arranz, M. et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346, 281–282 (1995).
  Article CAS Google Scholar
• Masellis, M. et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacol. 19, 123–132 (1998).
  Article CAS Google Scholar
• Joober, R. et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J. Psych. Neurosci. 24, 141–146 (1999).
  CAS Google Scholar
• Kuivenhoven, J. A. et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Engl. J. Med. 338, 86–93 (1998).
  Article CAS Google Scholar
• Drazen, J. M. et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168–170 (1999).
  Article CAS Google Scholar
• World Health Organization. Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetics Services <www.who.int/ncd/hgn/hgnethic.htm> (1997).
• Holtzman, N. A. & Watson, M. S. (eds) Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing (National Institutes of Health – Department of Energy Working Group on Ethical, Legal and Social Implications of Human Genome Research Task Force on Genetic Testing, Washington DC, 1997).
  Google Scholar
• Secretary's Advisory Committee on Genetic Testing. Enhancing the Oversight of Genetic Tests: Recommendations of the SACGT (2000).
• Robertson, J. A. Consent and privacy in pharmacogenetic testing. Nature Genet. 28, 207–209 (2001).This paper provides an overview of some of the consent and privacy issues that could potentially be ethically challenging once pharmacogenetics is used routinely in clinical practice.
  Article CAS Google Scholar
• Issa, A. M. Ethical considerations in clinical pharmacogenomics research. Trends Pharmacol. Sci. 21, 247–250 (2000).
  Article CAS Google Scholar
• Title 45, US Code of Federal Regulations (CFR), part 46. Protection of human subjects. 45CFR46.111(a)(1) <http://ohrp.osophs.dhhs.gov/>.
• Friedman, L. M., Furberg, C. D. & DeMets, D. L. Fundamentals of Clinical Trials (Wright, Boston, 1996).
  Google Scholar
• Council for International Organizations of Medical Sciences. International Ethical Guidelines for Biomedical Research Involving Human Subjects (Geneva, 1993).
• Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. A Report by a Working Group of the Three Federal Funding councils: Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada (1998).
• World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects, Adopted by the 18th WMA General Assembly Helsinki, Finland, 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland (2000).
• Emmanuel, E., Wendler, D. & Grady, C. What makes clinical research ethical? JAMA 283, 2701–2711 (2000).
  Article Google Scholar
• Murphy, M. P. et al. Prospective CYP2D6 genotyping as an exclusion criterion for enrolment of a Phase III clinical trial. Pharmacogenetics 10, 583–590 (2000).
  Article CAS Google Scholar
• Weber, W. W. Pharmacogenetics (Oxford Univ. Press, New York, 1997).
  Google Scholar
• March, R. Pharmacogenomics: the genomics of drug response. Yeast 17, 16–21 (2000).
  Article CAS Google Scholar
• Silverman, E. K. & Palmer, L. J. Case–control association studies for the genetics of complex respiratory diseases. Am. J. Respir. Cell. Mol. Biol. 22, 645–648 (2000).
  Article CAS Google Scholar
• Bird, T. D., Jarvik, G. P. & Wood, N. W. Genetic association studies: genes in search of diseases. Neurology 57, 1153–1154 (2001).
  Article CAS Google Scholar
• Roden, D. M. & George, A. L. The genetic basis of variability in drug responses. Nature Rev. Drug Discov. 1, 37–44 (2002).
  Article CAS Google Scholar
• McCarthy, J. J. & Hilfiker, R. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nature Biotechnol. 18, 505–508 (2000).
  Article CAS Google Scholar
• Cardon, L. R., Idury, R. M. & Harris, T. J. R. Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics 10, 503–510 (2000).
  Article CAS Google Scholar
• Long, A. D. & Langley, C. H. The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits. Genome Res. 9, 720–731 (1999).
  CAS Google Scholar
• Blacker, D. 2-Macroglobulin is genetically associated with Alzheimer disease. Nature Genet. 19, 357–360 (1998).
  Article CAS Google Scholar
• Dow, D. J. et al. α2-Macroglobulin polymorphism and Alzheimer disease risk in the UK. Nature Genet. 22, 16–17 (1999).
  Article CAS Google Scholar
• Rudransingham, V. et al. α2-Macroglobulin gene and Alzheimer disease. Nature Genet. 22, 17–19 (1999).
  Article Google Scholar
• Rogaeva, E. A. et al. An α2-Macroglobulin insertion–deletion polymorphism in Alzheimer disease. Nature Genet. 22, 19–21 (1999).
  Article CAS Google Scholar
• Editorial. Freely associating. Nature Genet. 22, 1–2 (1999).
• Butler, D. Epidemiology set to get fast-track treatment. Nature 414, 139 (2001)
  Article CAS Google Scholar
• Albert, S. M., Sano, M. & Marder, K. Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology 49, 38–43 (1997).
  Article CAS Google Scholar
• Knopman, D. et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 47, 166–177 (1996).
  Article CAS Google Scholar
• Issa, A. M. & Keyserlingk, E. W. Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: emerging ethical issues. Can. J. Psychiatry 45, 917–922 (2000).
  Article CAS Google Scholar
• Sterne, J. A. C. Sifting the evidence – what's wrong with significance tests? Br. Med. J. 322, 226–231.
• Becker, R. E. Modifying clinical trial designs to test treatments for clinical significance in individual patients. Clin. Drug Invest. 21, 727–733 (2001).
  Article Google Scholar
• Chen, S. et al. A genetic bias in clinical trials? Cytochrome P450-2D6 (CYP2D6) genotype in general vs selected healthy subject populations. Br. J. Clin. Pharmacol. 44, 303–304 (1997).
  CAS Google Scholar
• Bodenheimer, T. Uneasy alliance: clinical investigators and the pharmaceutical industry. New Engl. J. Med. 342, 1539–1544 (2000).
  Article CAS Google Scholar
• Zhao, H. Y. Family-based association studies. Stat. Methods Med. Res. 9, 563–587 (2000).
  Article CAS Google Scholar
• Jorde, L. B. Linkage disequilibrium and the search for complex disease genes. Genome Res. 10, 1435–1444 (2000).
  Article CAS Google Scholar
• Cardon, L. R. & Bell, J. L. Association study designs for complex diseases. Nature Rev. Genet. 2, 91–99 (2001).A thorough review that discusses different designs of genetic-association studies and their inherent limitations. Lessons from these studies need to be considered in thinking about the future design of pharmacogenomics trials.
  Article CAS Google Scholar
• Regaldo, A. Inventing the pharmacogenomics business. Am. J. Health Syst. Pharm. 56, 40–50 (1999).
  Article Google Scholar
• Persidis, A. The business of pharmacogenomics. Nature Biotechnol. 16, 209–210 (1998).
  Article CAS Google Scholar
• Fogarty, M. Up for adoption: pharmacogenetics and the orphan drug law. HMS Beagle [online] (cited 01 Mar. 02) <http://www.biomednet.com/hmsbeagle/44/op_ed.htm> (1998).
• Food and Drug Administration. Miscellaneous provisions relating to the Orphan Drug Act. Food and Drug Administration (cited 01 Mar 02) <htpp://www.fda.gov/opacom/laws/orphandg.htm> (2001).
• National Organization for Rare Diseases (NORD). Understanding the Orphan Drug Act (cited 01 Mar 02) <http://www.rarediseases.org/cgi-bin/nord> (2001).
• Europarliament. Scientific and Technological Options Assessment. Orphan Drug Status Initiatives in the Different Countries (cited 01 Mar 02) <http://www.europarl.eu.int/home/default_en.htm>.
• Moses, H. & Martin, J. B. Academic relationships with industry: a new model for biomedical research. JAMA 285, 933–935 (2001).
  Article Google Scholar
• Bains, W. The long-term value of genomics companies. J. Chem. Technol. Biotechnol. 75, 883–900 (2000).
  Article CAS Google Scholar
• Aronowitz, R. A. Making Sense of Illness: Science, Society and Disease. (Cambridge Univ. Press, Cambridge, UK, 1998).
  Google Scholar
• Todd, J. A. Interpretation of results from genetic studies of multifactorial diseases. Lancet 354 (Suppl. 1), 15–16 (1999).
  Article Google Scholar
• Patino, C. M. & Martinez, F. D. Interactions between genes and environment in the development of asthma. Allergy 56, 279–286 (2001).
  Article CAS Google Scholar
• Ingelman-Sundberg, M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Int. Med. 250, 186–200 (2001).
  Article CAS Google Scholar